Literature DB >> 26710749

Both heat and new chemotherapeutic drug dioxadet in hyperthermic intraperitoneal chemoperfusion improved survival in rat ovarian cancer model.

Vladimir G Bespalov1,2, Galina S Kireeva1,2, Olesya A Belyaeva1,2, Oleksiy E Kalinin3, Konstantin Y Senchik1, Alexandr N Stukov1, Georgy I Gafton1, Konstantin D Guseynov1, Alexey M Belyaev1.   

Abstract

BACKGROUND AND OBJECTIVES: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the time of Cytoreductive Surgery (CRS) is an actively researched treatment in patients with advanced ovarian cancer. Relative contribution of heat and chemotherapeutic agents during HIPEC as well as efficacy of a new agent dioxadet for regional chemotherapy in a rat model of ovarian cancer was studied.
METHODS: Sixty rats were divided into three groups: no treatment control group (n = 19), hyperthermia without chemotherapy (HIPEP) (n = 14), HIPEC + cisplatin (n = 14), HIPEC + dioxadet (n = 13). The intra-abdominal tumor was not resected. End points were: median survival (primary), cause of death (secondary).
RESULTS: The median survival of the animals in the control group, HIPEP group, HIPEC + cisplatin, HIPEC + dioxadet were 9 (CI; 8-23), 22.5 (CI; 12-43), 25.5 (CI; 13-62), 49 (Cl; 28-70) days, respectively. The P-values control versus HIPEP, HIPEC + cisplatin versus HIPEC + dioxadet were 0.006, 0.002, and 0.001, respectively.
CONCLUSION: During HIPEC both the heat and the cytotoxic drug had antitumor effects in a rat ovarian cancer model. Dioxadet showed potential as a drug for regional chemotherapy. J. Surg. Oncol. 2016;113:438-442.
© 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  cisplatin; dioxadet; hyperthermic intraperitoneal chemoperfusion (HIPEC); ovarian cancer; peritoneal carcinomatosis

Mesh:

Substances:

Year:  2015        PMID: 26710749     DOI: 10.1002/jso.24140

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  3 in total

1.  Morphological changes in the ovarian carcinoma cells of Wistar rats induced by chemotherapy with cisplatin and dioxadet.

Authors:  A A Zhikhoreva; A V Belashov; V G Bespalov; A L Semenov; I V Semenova; G V Tochilnikov; N T Zhilinskaya; O S Vasyutinskii
Journal:  Biomed Opt Express       Date:  2018-10-29       Impact factor: 3.732

Review 2.  Narrative review of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced ovarian cancer: a critical reappraisal of the current evidence.

Authors:  John Spiliotis; Anastasia Prodromidou
Journal:  J Gastrointest Oncol       Date:  2021-04

3.  Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma.

Authors:  Galina Kireeva; Ekaterina Gubareva; Mikhail Maydin; Vladislav Osetnik; Stepan Kruglov; Andrey Panchenko; Anastasia Dorofeeva; Margarita Tyndyk; Elena Fedoros; Vladimir Anisimov
Journal:  Onco Targets Ther       Date:  2021-05-24       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.